Pro-Resolving Mediators in Inflammatory Pain Management

Pro-resolving mediators are a class of endogenously generated lipid compounds that orchestrate the active resolution phase of inflammation and offer novel pathways for pain control. Derived from polyunsaturated fatty acids, these specialised mediators—including lipoxins, resolvins, protectins and maresins—bind to distinct G-protein coupled receptors on immune cells and nociceptive neurons. By terminating leukocyte recruitment, promoting macrophage clearance of debris and attenuating pro-inflammatory cytokine release, they not only accelerate tissue repair but also dampen peripheral and central sensitisation underlying inflammatory pain. Recent advances have revealed that pro-resolving mediators can inhibit key ion channels such as TRPV1 and TRPA1, prevent spinal release of tumour necrosis factor and interleukins, and modulate glial cell function. These findings point to a paradigm shift away from merely suppressing inflammation towards harnessing endogenous resolution circuits. Practical applications under investigation range from topical formulations and peri-operative infusions of omega-3-derived lipid precursors to receptor-targeted agonists, offering the prospect of efficacy without the adverse effects associated with traditional analgesics. The global burden of chronic inflammatory pain, coupled with the limitations of current therapies, has stimulated interdisciplinary research aimed at translating these lipid mediators into safe, disease-modifying treatments.

Research from Nature Portfolio

Investigations in human cohorts have explored the association between circulating levels of the resolvin precursor 17-hydroxy-docosahexaenoic acid (17-HDHA) and pain sensitivity. Analyses reveal that higher 17-HDHA concentrations correlate with increased heat-pain thresholds in healthy volunteers and reduced pain scores in individuals with osteoarthritis, independent of structural joint changes. These data suggest that modulation of D-series resolvin pathways may be a viable strategy for alleviating clinical symptoms of inflammatory joint pain and point to endogenous 17-HDHA as both a biomarker and potential therapeutic precursor.

Pro-Resolving Mediators in Inflammatory Pain Management publication trend

The graph below shows the total number of articles in pro-resolving mediators in inflammatory pain management across all publications each year (not limited to Nature Index journals).

Technical terms

Specialised pro-resolving mediators (SPMs): Endogenous lipid autacoids derived from polyunsaturated fatty acids that actively drive the resolution phase of inflammation and modulate pain pathways.

Resolvin: A subset of SPMs biosynthesised from omega-3 fatty acids (EPA and DHA) that suppress pro-inflammatory signals and reduce neuronal sensitisation.

Lipoxin: An arachidonic acid-derived lipid mediator that terminates neutrophil recruitment, stimulates macrophage clearance and attenuates inflammatory pain.

Maresin: Macrophage-derived mediators formed from DHA that promote tissue regeneration and inhibit nociceptive receptor activity.

Transient receptor potential (TRP) channels: A family of ion channels, including TRPV1 and TRPA1, expressed on sensory neurons that transduce thermal and chemical nociceptive stimuli.

References

1. The analgesic effects of Yu-Xue-Bi tablet (YXB) on mice with inflammatory pain by regulating LXA4-FPR2-TRPA1 pathway. Chinese Medicine (2024).
2. Role of Resolvins in Inflammatory and Neuropathic Pain. Pharmaceuticals (2023).
3. Association of the resolvin precursor 17-HDHA, but not D- or E- series resolvins, with heat pain sensitivity and osteoarthritis pain in humans. Scientific Reports (2017).
4. Distinct Analgesic Actions of DHA and DHA-Derived Specialized Pro-Resolving Mediators on Post-operative Pain After Bone Fracture in Mice. Frontiers in Pharmacology (2018).
5. Spinal Actions of Lipoxin A4 and 17(R)-Resolvin D1 Attenuate Inflammation-Induced Mechanical Hypersensitivity and Spinal TNF Release. PLOS ONE (2013).
6. Specialized Pro-resolving Lipid Mediators and Glial Cells: Emerging Candidates for Brain Homeostasis and Repair. Frontiers in Cellular Neuroscience (2021).
7. Maresin 1 Inhibits TRPV1 in Temporomandibular Joint‐Related Trigeminal Nociceptive Neurons and TMJ Inflammation‐Induced Synaptic Plasticity in the Trigeminal Nucleus. Mediators of Inflammation (2015).